 | Up a level |
Rentsch, Cyrill A; Bosshard, Piet; Mayor, Grégoire; Rieken, Malte; Püschel, Heike; Wirth, Grégory; Cathomas, Richard; Parzmair, Gerald P; Grode, Leander; Eisele, Bernd; Sharma, Hitt; Gupta, Manish; Gairola, Sunil; Shaligram, Umesh; Goldenberger, Daniel; Spertini, François; Audran, Régine; Enoiu, Milica; Berardi, Simona; Hayoz, Stefanie; ... (2020). Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. Oncoimmunology, 9(1), p. 1748981. Taylor & Francis 10.1080/2162402X.2020.1748981
Le Magnen, Clémentine; Bubendorf, Lukas; Rentsch, Cyrill A.; Mengus, Chantal; Gsponer, Joel; Zellweger, Tobias; Rieken, Malte; Thalmann, George N.; Cecchini, Marco G.; Germann, Markus; Bachmann, Alexander; Wyler, Stephen; Heberer, Michael; Spagnoli, Giulio C. (2013). Characterization and Clinical Relevance of ALDHbright Populations in Prostate Cancer. Clinical cancer research, 19(19), pp. 5361-5371. American Association for Cancer Research 10.1158/1078-0432.CCR-12-2857
